Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation

被引：8
|
作者：
Jentzsch, Madlen [1 ]
Grimm, Juliane [1 ]
Bill, Marius [1 ]
Brauer, Dominic [1 ]
Backhaus, Donata [1 ]
Pointner, Rosmarie [1 ]
Goldmann, Karoline [1 ]
Schulz, Julia [1 ]
Niederwieser, Dietger [1 ]
Platzbecker, Uwe [1 ]
Schwind, Sebastian [1 ]
机构：
[1] Leipzig Univ Hosp, Med Clin & Policlin 1, Hematol & Cellular Therapy, Liebigstr 22,Haus 7, D-04103 Leipzig, Germany
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2021年 / 96卷 / 07期
关键词：
D O I：
10.1002/ajh.26179
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E237 / E239
页数：3
相关论文
共 50 条
  • [31] Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML
    Morsink, Linde M.
    Othus, Megan
    Bezerra, Evandro D.
    Wood, Brent L.
    Fang, Min
    Sandmaier, Brenda M.
    Mielcarek, Marco
    Schoch, Gary
    Storb, Rainer
    Deeg, H. Joachim
    Appelbaum, Frederick R.
    Walter, Roland B.
    LEUKEMIA, 2020, 34 (06) : 1577 - 1587
  • [32] Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML
    Linde M. Morsink
    Megan Othus
    Evandro D. Bezerra
    Brent L. Wood
    Min Fang
    Brenda M. Sandmaier
    Marco Mielcarek
    Gary Schoch
    Rainer Storb
    H. Joachim Deeg
    Frederick R. Appelbaum
    Roland B. Walter
    Leukemia, 2020, 34 : 1577 - 1587
  • [33] Clinical risk factors for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation
    Teshigawara-Tanabe, Haruka
    Hagihara, Maki
    Aoki, Jun
    Koyama, Satoshi
    Takahashi, Hiroyuki
    Nakajima, Yuki
    Kunimoto, Hiroyoshi
    Tachibana, Takayoshi
    Miyazaki, Takuya
    Matsumoto, Kenji
    Tanaka, Masatsugu
    Yamazaki, Etsuko
    Fujisawa, Shin
    Kanamori, Heiwa
    Taguri, Masataka
    Nakajima, Hideaki
    HEMATOLOGY, 2022, 27 (01) : 620 - 628
  • [34] The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation
    Arnon Nagler
    Bhagirathbhai Dholaria
    Myriam Labopin
    Gerard Socie
    Anne Huynh
    Maija Itälä-Remes
    Eric Deconinck
    Ibrahim Yakoub-Agha
    Jean-Yves Cahn
    Jean-Henri Bourhis
    Hélène Labussière-Wallet
    Sylvain Chantepie
    Jordi Esteve
    Bipin Savani
    Mohamad Mohty
    Leukemia, 2020, 34 : 1144 - 1153
  • [35] The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation
    Nagler, Arnon
    Dholaria, Bhagirathbhai
    Labopin, Myriam
    Socie, Gerard
    Huynh, Anne
    Itaelae-Remes, Maija
    Deconinck, Eric
    Yakoub-Agha, Ibrahim
    Cahn, Jean-Yves
    Bourhis, Jean-Henri
    Labussiere-Wallet, Helene
    Chantepie, Sylvain
    Esteve, Jordi
    Savani, Bipin
    Mohty, Mohamad
    LEUKEMIA, 2020, 34 (04) : 1144 - 1153
  • [36] ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
    Hansen, Doris K.
    Kim, Jongphil
    Thompson, Zachary
    Hussaini, Mohammad
    Nishihori, Taiga
    Ahmad, Anam
    Elmariah, Hany
    Faramand, Rawan
    Mishra, Asmita
    Davila, Marco L.
    Khimani, Farhad
    Lazaryan, Aleksandr
    Sallman, David
    Liu, Hien
    Perez, Lia E.
    Fernandez, Hugo
    Nieder, Michael L.
    Lancet, Jeffrey E.
    Pidala, Joseph A.
    Anasetti, Claudio
    Bejanyan, Nelli
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (03): : 256.e1 - 256.e7
  • [37] Nutrition status and management of patients undergoing allogeneic hematopoietic stem cell transplantation
    Osborne, Jacqueline
    Cassar, Olivia
    Wittholz, Kym
    Griffin, Hilda
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 259 - 259
  • [38] Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD-Mutated AML Following Allogeneic Hematopoietic Cell Transplantation
    Liang, Emily C.
    Chen, Connie
    Lu, Rong
    Mannis, Gabriel N.
    Muffly, Lori
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S278 - S279
  • [39] Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD Mutated AML Following Allogeneic Hematopoietic Cell Transplantation
    Liang, Emily C.
    Chen, Connie
    Lu, Rong
    Mannis, Gabriel N.
    Muffly, Lori
    BLOOD, 2021, 138
  • [40] Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation
    Lucero, Josephine
    Alhumaid, Muhned
    Novitzky-Basso, Igor
    Capo-Chichi, Jose-Mario
    Stockley, Tracy
    Gupta, Vikas
    Bankar, Aniket
    Chan, Steven
    Schuh, Andre C.
    Minden, Mark
    Mattsson, Jonas
    Kumar, Rajat
    Sibai, Hassan
    Tierens, Anne
    Kim, Dennis D. H.
    ANNALS OF HEMATOLOGY, 2024, 103 (04) : 1187 - 1196
12345